- Home
- APLT vs SNTI Comparison
APLT vs SNTI Comparison
Compare APLT & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- SNTI
- Stock Information
- Founded
- APLT 2016
- SNTI 2016
- Country
- APLT United States
- SNTI United States
- Employees
- APLT N/A
- SNTI N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- APLT Health Care
- SNTI Health Care
- Exchange
- APLT Nasdaq
- SNTI Nasdaq
- Market Cap
- APLT 44.0M
- SNTI 50.3M
- IPO Year
- APLT 2019
- SNTI N/A
- Fundamental
- Price
- APLT $0.45
- SNTI $1.70
- Analyst Decision
- APLT Buy
- SNTI Strong Buy
- Analyst Count
- APLT 7
- SNTI 2
- Target Price
- APLT $6.10
- SNTI $8.50
- AVG Volume (30 Days)
- APLT 1.6M
- SNTI 511.1K
- Earning Date
- APLT 08-11-2025
- SNTI 08-12-2025
- Dividend Yield
- APLT N/A
- SNTI N/A
- EPS Growth
- APLT N/A
- SNTI N/A
- EPS
- APLT N/A
- SNTI N/A
- Revenue
- APLT $265,000.00
- SNTI N/A
- Revenue This Year
- APLT $415.60
- SNTI N/A
- Revenue Next Year
- APLT $1,323.96
- SNTI $150.00
- P/E Ratio
- APLT N/A
- SNTI N/A
- Revenue Growth
- APLT N/A
- SNTI N/A
- 52 Week Low
- APLT $0.30
- SNTI $1.52
- 52 Week High
- APLT $10.62
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- APLT 53.55
- SNTI 29.96
- Support Level
- APLT $0.46
- SNTI $1.86
- Resistance Level
- APLT $0.54
- SNTI $2.12
- Average True Range (ATR)
- APLT 0.05
- SNTI 0.15
- MACD
- APLT -0.00
- SNTI 0.00
- Stochastic Oscillator
- APLT 53.66
- SNTI 0.00
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.